SeqOne Genomics and the French CNR-MAT pioneer the use of Oxford Nanopore sequencing technology to improve outcomes in kidney disease while reducing turnaround times

SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies(CNR-MAT), aimed at improving outcomes in thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS), using Oxford Nanopore sequencing technology.

You can read the full announcement from SeqOne here.